NICE recommends peginterferon-α

PharmacoEconomics & Outcomes News 689, p11 - 19 Oct 2013 NICE recommends peginterferon-α NICE has published final draft guidance recommending the use of both peginterferon-α-2a [Pegasys] and peginterferon-α-2b [ViraferonPeg], in combination with ribavirin, for the treatment of children and adolescents with hepatitis C. 1 Treatment with either drug (plus ribavirin) was less costly and more effective than best supportive care, but the appraisal committee said that it could not recommend one treatment over the other because the submitted data were "not robust enough". Faecal calprotectin test gets the nod too NICE has also recommended the use of a simple faecal test to distinguish between potentially serious inflammatory bowel disease (IBD) and less serious irritable bowel syndrome (IBS). 2 The test, which measures the levels of the protein calprotectin found in inflammatory cells, is expected to save the NHS money as well as being of benefit to patients. Specifically, the tests will reduce both the time spent searching for a diagnosis and the numbers of invasive procedures such as colonoscopy. But still no luck for pixantrone However, in third draft guidance, NICE has said that it still cannot recommended pixantrone [Pixuvri] as a treatment for multiply relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. 3 The decision comes after the manufacturer of pixantrone submitted a patient access scheme to the independent Appraisal Committee. However, the committee estimated that even with this scheme the most likely incremental cost effectiveness ratio was £30 700 per QALY – not a "a cost- effective use of NHS resources", says NICE. Consultation on this draft guidance is open until 4 November 2013. 1. NICE. NICE final draft guidance recommends drugs to treat chronic hepatitis C in children and young people. Media Release : 9 Oct 2013. Available from: URL: http://www.nice.org.uk. 2. NICE. NICE recommends tests to help diagnose serious bowel conditions. Media Release : 1 Oct 2013. Available from: URL: http://www.nice.org.uk. 3. NICE. NICE consults again on non-Hodgkin’s lymphoma treatment. Media Release : 11 Oct 2013. Available from: URL: http://www.nice.org.uk. 801085746 1 PharmacoEconomics & Outcomes News 19 Oct 2013 No. 689 1173-5503/13/0689-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

Upload
yuying
Category

Documents
view
213
download
0

Embed Size (px):

Transcript of NICE recommends peginterferon-α

PharmacoEconomics & Outcomes News 689, p11 - 19 Oct 2013

NICE recommends peginterferon-αNICE has published final draft guidance

recommending the use of both peginterferon-α-2a[Pegasys] and peginterferon-α-2b [ViraferonPeg], incombination with ribavirin, for the treatment of childrenand adolescents with hepatitis C.1 Treatment with eitherdrug (plus ribavirin) was less costly and more effectivethan best supportive care, but the appraisal committeesaid that it could not recommend one treatment over theother because the submitted data were "not robustenough".

Faecal calprotectin test gets the nod tooNICE has also recommended the use of a simple

faecal test to distinguish between potentially seriousinflammatory bowel disease (IBD) and less seriousirritable bowel syndrome (IBS).2 The test, whichmeasures the levels of the protein calprotectin found ininflammatory cells, is expected to save the NHS moneyas well as being of benefit to patients. Specifically, thetests will reduce both the time spent searching for adiagnosis and the numbers of invasive procedures suchas colonoscopy.

But still no luck for pixantroneHowever, in third draft guidance, NICE has said that it

still cannot recommended pixantrone [Pixuvri] as atreatment for multiply relapsed or refractory aggressiveB-cell non-Hodgkin’s lymphoma.3 The decision comesafter the manufacturer of pixantrone submitted a patientaccess scheme to the independent AppraisalCommittee. However, the committee estimated thateven with this scheme the most likely incremental costeffectiveness ratio was £30 700 per QALY – not a "a cost-effective use of NHS resources", says NICE. Consultationon this draft guidance is open until 4 November 2013.1. NICE. NICE final draft guidance recommends drugs to treat chronic hepatitis C

in children and young people. Media Release : 9 Oct 2013. Available from:URL: http://www.nice.org.uk.

2. NICE. NICE recommends tests to help diagnose serious bowel conditions.Media Release : 1 Oct 2013. Available from: URL: http://www.nice.org.uk.

3. NICE. NICE consults again on non-Hodgkin’s lymphoma treatment. MediaRelease : 11 Oct 2013. Available from: URL: http://www.nice.org.uk.

801085746